This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PDL BioPharma Inc (PDLI)

: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 554.25M 533.21M 442.92M 374.52M
Cost of Sales 0.00 0.00 5.64M 0.00
Gross Operating Profit 554.25M 533.21M 437.28M 374.52M
Selling, General, and Administrative Expenses 36.09M 34.91M 29.75M 25.47M
Research & Development 0.00 0.00 0.00 0.00
Operating Income before D & A (EBITDA) 518.16M 498.29M 407.53M 349.06M
Depreciation & Amortization 13.00M 18.83M 18.55M 14.65M
Interest Income 368.00K 48.02M 19.22M 7.11M
Other Income - Net 38.67M -5.83M 0.00 0.00
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) 544.19M 521.65M 408.19M 341.52M
Interest Expense 27.06M 39.21M 24.87M 29.04M
Pre-Tax Income 517.13M 482.44M 383.32M 312.48M
Income Taxes 197.34M 179.03M 137.35M 115.46M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 332.80M 322.24M 264.53M 211.67M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 332.80M 322.24M 264.53M 211.67M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 332.80M 322.24M 264.53M 211.67M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
332.80M 322.24M 264.53M 211.67M
Preferred Dividends
Net Income Available To Common 332.80M 322.24M 264.53M 211.67M
Basic EPS from Continuing Ops. 2.04 2.04 1.89 1.52
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 2.04 2.04 1.89 1.52
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 2.04 2.04 1.89 1.52
Basic Normalized Net Income/Share 2.04 2.04 1.89 1.52
EPS fr Continuing Ops. 2.03 1.86 1.66 1.45
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 2.03 1.86 1.66 1.45
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 2.03 1.86 1.66 1.45
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
2.03 1.86 1.66 1.45
Dividends Paid per Share 0.60 0.60 0.60 0.60
PDLI News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

PDLI PDL BioPharma Inc

Chart of PDLI

Analysts Ratings for PDLI

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET PDLI ANALYST REPORT

PDLI Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs